Radiopharmaceutical · Acts on Large Neutral Amino Acid Transporter 1 and 2 (LAT1/LAT2) (SLC7A5) · developed by Telix
Floretyrosine F 18 is a fluorine-18 labeled tyrosine analog and PET tracer that is taken up through the large neutral amino acid transporters LAT1 and LAT2, which are highly expressed in glioma tissue. It is studied for imaging brain metastases to distinguish tumor progression from treatment-related changes.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Oct 7, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07931261 | Phase 3 | Brain Metastasis | Not yet recruiting | TLX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Brain MetastasisPseudoprogressionRadiation NecrosisTumor Progression
Updated Nov 15, 2026. Something wrong or missing? Report it on the TLX page.
See TLX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TLX catalysts and pipeline →